Abstract |
There is a need for novel, effective, and cell- and gene-specific therapeutics for cancer. Modified oligonucleotides can be used to modulate specifically and potently the expression of several genes that are upregulated in breast and prostate cancer and have been found to be causal to the tumor phenotype. Synergistic downregulation of these genes may be a potent therapeutic intervention. We are investigating the use of boranophosphate (BP) analogues of RNA as promising candidates for enhancing the potential of three relatively new, gene-specific, anticancer strategies: (1) Tumor-targeted borane siRNA against a combination of genes that control metabolism and transduction; (2) Tumor-specific modified aptamers against prostate specific membrane antigen (PSMA) and ERB2 in breast cancer as delivery agents; and (3) Cancer cell obliteration by cell-specific radiation therapy: Boron-Neutron-Capture-Therapy.
|
Authors | Barbara Ramsay Shaw, Laura Moussa, Mariam Sharaf, Marcus Cheek, Mikhail Dobrikov |
Journal | Nucleic acids symposium series (2004)
(Nucleic Acids Symp Ser (Oxf))
Issue 52
Pg. 655-6
( 2008)
ISSN: 1746-8272 [Electronic] England |
PMID | 18776550
(Publication Type: Journal Article, Research Support, N.I.H., Extramural)
|
Chemical References |
- Antigens, Surface
- Aptamers, Nucleotide
- Boranes
- Phosphates
- RNA, Small Interfering
- boranophosphate
- Receptor, ErbB-2
- FOLH1 protein, human
- Glutamate Carboxypeptidase II
|
Topics |
- Antigens, Surface
(genetics)
- Aptamers, Nucleotide
(chemistry)
- Boranes
(chemistry)
- Boron Neutron Capture Therapy
- Breast Neoplasms
(therapy)
- Cell Line, Tumor
- Down-Regulation
- Female
- Glutamate Carboxypeptidase II
(antagonists & inhibitors, genetics)
- Humans
- Male
- Neoplasms
(radiotherapy, therapy)
- Phosphates
(chemistry)
- Prostatic Neoplasms
(therapy)
- RNA Interference
- RNA, Small Interfering
(chemistry)
- Receptor, ErbB-2
(antagonists & inhibitors, genetics)
|